Antipsychotics for children and young adults: A comparative effectiveness review

Pediatrics

Volumn 129, Issue 3, 2012, Pages

  Seida, Jennifer C ^a   Schouten, Janine R ^a   Boylan, Khrista ^c,d   Newton, Amanda S ^b   Mousavi, Shima S ^a   Beaith, Amy ^a   Vandermeer, Ben ^a   Dryden, Donna M ^a   Carrey, Normand ^e,f  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d McMaster University and Hamilton Health Sciences McMaster Innovation Park   (Canada)

^e DALHOUSIE UNIVERSITY   (Canada)

^f MCGILL UNIVERSITY   (Canada)

Author keywords

Antipsychotics; Behavioral disorders; Psychiatric disorders; Systematic review

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; FIRST GENERATION ANTIPSYCHOTIC AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PIMOZIDE; PLACEBO; QUETIAPINE; RISPERIDONE; SECOND GENERATION ANTIPSYCHOTIC AGENT; UNCLASSIFIED DRUG; ZIPRASIDONE;

ADOLESCENT; ATTENTION DEFICIT DISORDER; AUTISM; BEHAVIOR DISORDER; BIPOLAR DISORDER; CHILD; CHILD HEALTH CARE; COHORT ANALYSIS; CONTINUOUS INFUSION; DATA ANALYSIS; DATA BASE; DATA EXTRACTION; DISRUPTIVE BEHAVIOR; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; ENDOCRINE DISEASE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GILLES DE LA TOURETTE SYNDROME; HUMAN; INSULIN RESISTANCE; INTERNAL BIAS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; META ANALYSIS (TOPIC); METHODOLOGY; OFF LABEL DRUG USE; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; PROLACTIN RELATED ADVERSE EVENT; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SCHOOL CHILD; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT CHANGE;

ADOLESCENT; AGE FACTORS; ANTIPSYCHOTIC AGENTS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; MENTAL DISORDERS; MOOD DISORDERS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SCHIZOPHRENIA; SEX FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84857952277     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2011-2158     Document Type: Review

References (111)

1. Zito JM, Safer DJ, dosReis S, Gardner JF, Boles M, Lynch F. Trends in the prescribing of psychotropic medications to preschoolers. JAMA. 2000;283(8):1025-1030 (Pubitemid 30112216)
2. Zito JM, Safer DJ, DosReis S, et al. Psychotropic practice patterns for youth: a 10-year perspective. Arch Pediatr Adolesc Med. 2003;157(1):17-25 (Pubitemid 36343413)
3. Zito JM, Safer DJ, de Jong-van den Berg LT, et al. A three-country comparison of psychotropic medication prevalence in youth. Child Adolesc Psychiatry Ment Health. 2008;2(1):26
4. Zito JM, Safer DJ, Sai D, et al. Psychotropic medication patterns among youth in foster care. Pediatrics. 2008;121(1). Available at: www.pediatrics.org/cgi/content/full/121/1/e157
5. Aparasu RR, Bhatara V. Patterns and determinants of antipsychotic prescribing in children and adolescents, 2003-2004. Curr Med Res Opin. 2007;23(1):49-56 (Pubitemid 46191669)
6. Pathak S, Arszman SP, Danielyan A, Johns ES, Smirnov A, Kowatch RA. Psychotropic utilization and psychiatric presentation of hospitalized very young children. J Child Adolesc Psychopharmacol. 2004;14(3):433-442 (Pubitemid 39473129)
7. Rani F, Murray ML, Byrne PJ, Wong IC. Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom. Pediatrics. 2008;121(5):1002-1009
8. Alexander GC, Gallagher SA, Mascola A, Moloney RM, Stafford RS. Increasing offlabel use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiol Drug Saf. 2011;20(2):177-184
9. Cooper WO, Arbogast PG, Ding H, Hickson GB, Fuchs DC, Ray WA. Trends in prescribing of antipsychotic medications for US children. Ambul Pediatr. 2006;6(2):79-83 (Pubitemid 43960577)
10. De Hert M, Dobbelaere M, Sheridan EM, Cohen D, Correll CU. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry. 2011;26(3):144-158
11. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(suppl 1):1-93 Shekelle P, Maglione M, Bagley S, et al. Comparative Effectiveness of Off-Label Use of Atypical Antipsychotics. Comparative Effectiveness Review No. 6. (Prepared by the Southern California/RAND Evidence-based Practice Center under Contract No. 290-02-0003). Rockville, MD: Agency for Healthcare Research and Quality; 2007 (Pubitemid 40677047)
12. Jensen PS, Buitelaar J, Pandina GJ, Binder C, Haas M. Management of psychiatric disorders in children and adolescents with atypical antipsychotics: a systematic review of published clinical trials. Eur Child Adolesc Psychiatry. 2007;16(2):104-120 (Pubitemid 46643895)
13. Stachnik JM, Nunn-Thompson C. Use of atypical antipsychotics in the treatment of autistic disorder. Ann Pharmacother. 2007;41(4):626-634 (Pubitemid 46625485)
14. Consoli A, Deniau E, Huynh C, Purper D, Cohen D. Treatments in child and adolescent bipolar disorders. Eur Child Adolesc Psychiatry. 2007;16(3):187-198 (Pubitemid 46664134)
15. Kennedy E, Kumar A, Datta S. Antipsychotic medication for childhood-onset schizophrenia. Cochrane Database Syst Rev. 2007;(3):CD004027
16. Armenteros JL, Davies M. Antipsychotics in early onset schizophrenia: systematic review and meta-analysis. Eur Child Adolesc Psychiatry. 2006;15(3):141-148
17. Ipser JC, Stein DJ. A systematic review of the quality and impact of anxiety disorder meta-analyses. Curr Psychiatry Rep. 2009; 11(4):302-309
18. Pappadopulos E, Woolston S, Chait A, Perkins M, Connor DF, Jensen PS. Pharmacotherapy of aggression in children and adolescents: efficacy and effect size. J Can Acad Child Adolesc Psychiatry. 2006;15(1):27-39
19. Jensen PS, Buitelaar J, Pandina GJ, Binder C, Haas M. Management of psychiatric disorders in children and adolescents with atypical antipsychotics: a systematic review of published clinical trials. Eur Child Adolesc Psychiatry. 2007;16(2):104-120 (Pubitemid 46643895)
20. Higgins J, Green S, eds. Cochrane handbook for systematic reviews of interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration 2008. Available at: www.mrc-bsu.cam.ac.uk/cochrane/handbook/front-page.htm. Accessed September 19, 2011
21. Wells G, Shea B, O'Connell N, et al. Department of Epidemiology and Community Medicine, University of Ottawa. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Available at: www.ohri.ca/programs/ clinical-epidemiology/oxford.asp. Accessed September 19, 2011
22. Sismondo S. Pharmaceutical company funding and its consequences: a qualitative systematic review. Contemp Clin Trials. 2008;29(2):109-113 (Pubitemid 351248768)
23. Owens DK, Lohr KN, Atkins D, et al. AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions-Agency for Healthcare Research and Quality and the effective health-care program. J Clin Epidemiol. 2010;63(5):513-523
24. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539-1558 (Pubitemid 34746062)
25. Deeks J, Altman D, Bradburn M. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Davey Smith G, Altman DG, eds. Systematic Review in Health Care: Meta-Analysis in Context. 2nd ed. London, UK: BMJ Publishing Group; 2001:285-312
26. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315 (7109):629-634 (Pubitemid 27387172)
27. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in metaanalysis. Biometrics. 2000;56(2):455-463 (Pubitemid 30422636)
28. Hollander E, Wasserman S, Swanson EN, et al. A double-blind placebo-controlled pilot study of olanzapine in childhood/ adolescent pervasive developmental disorder. J Child Adolesc Psychopharmacol. 2006;16(5):541-548 (Pubitemid 44737209)
29. Luby J, Mrakotsky C, Stalets MM, et al. Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy. J Child Adolesc Psychopharmacol. 2006;16(5):575-587 (Pubitemid 44737212)
30. Malone RP, Cater J, Sheikh RM, Choudhury MS, Delaney MA. Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. J Am Acad Child Adolesc Psychiatry. 2001;40(8):887-894 (Pubitemid 32667070)
31. Marcus RN, Owen R, Kamen L, et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2009;48(11):1110-1119
32. McCracken JT, McGough J, Shah B, et al Research Units on Pediatric Psychopharmacology Autism Network. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002;347(5):314-321 (Pubitemid 34815353)
33. Miral S, Gencer O, Inal-Emiroglu FN, Baykara B, Baykara A, Dirik E. Risperidone versus haloperidol in children and adolescents with AD : a randomized, controlled, double-blind trial. Eur Child Adolesc Psychiatry. 2008;17(1):1-8
34. Nagaraj R, Singhi P, Malhi P. Risperidone in children with autism: randomized, placebo-controlled, double-blind study. J Child Neurol. 2006;21(6):450-455 (Pubitemid 44069792)
35. Aman M. NCT00576732. A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder. Johnson & Johnson Pharmaceutical Research and Development; 2010
36. Perry R, Campbell M, Adams P, et al. Long-term efficacy of haloperidol in autistic children: continuous versus discontinuous drug administration. J Am Acad Child Adolesc Psychiatry. 1989;28(1):87-92 (Pubitemid 19037885)
37. Shea S, Turgay A, Carroll A, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics. 2004;114(5). Available at: www.pediatrics.org/cgi/content/full/114/5/e634
38. Troost PW, Lahuis BE, Steenhuis MP, et al. Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. J Am Acad Child Adolesc Psychiatry. 2005;44(11):1137-1144 (Pubitemid 41508125)
39. Novaes CM, Pondé MP, Freire AC. Control of psychomotor agitation and aggressive behavior in patients with autistic disorder: a retrospective chart review. Arq Neuropsiquiatr. 2008;66(3B):646-651
40. Armenteros JL, Lewis JE, Davalos M. Risperidone augmentation for treatmentresistant aggression in attention-deficit/hyperactivity disorder: a placebo-controlled pilot study. J Am Acad Child Adolesc Psychiatry. 2007;46(5):558-565 (Pubitemid 46642572)
41. Connor DF, McLaughlin TJ, Jeffers-Terry M. Randomized controlled pilot study of quetiapine in the treatment of adolescent conduct disorder. J Child Adolesc Psychopharmacol. 2008;18(2):140-156 (Pubitemid 351591434)
42. Aman MG, Hollway JA, Leone S, et al. Effects of risperidone on cognitive-motor performance and motor movements in chronically medicated children. Res Dev Disabil. 2009;30(2):386-396
43. Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL; Risperidone Disruptive Behavior Study Group. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry. 2002;159(8):1337-1346 (Pubitemid 34832715)
44. Buitelaar JK, van der Gaag RJ, Cohen- Kettenis P, Melman CT. A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. J Clin Psychiatry. 2001;62(4):239-248 (Pubitemid 32428762)
45. Findling RL, McNamara NK, Branicky LA, Schluchter MD, Lemon E, Blumer JL. A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry. 2000;39(4):509-516 (Pubitemid 30185547)
46. Reyes M, Buitelaar J, Toren P, Augustyns I, Eerdekens M. A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. Am J Psychiatry. 2006;163(3):402-410 (Pubitemid 44469381)
47. Snyder R, Turgay A, Aman M, Binder C, Fisman S, Carroll A; Risperidone Conduct Study Group. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry. 2002;41(9):1026-1036 (Pubitemid 38338050)
48. Biederman J, Mick E, Hammerness P, et al. Open-label, 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder in preschool-age children. Biol Psychiatry. 2005;58(7):589-594 (Pubitemid 41457306)
49. Biederman J, Mick E. Comparative openlabel trial of atypical neuroleptics in children and adolescents with bipolar disorder [abstract]. Eur Neuropsychopharmacol. 2004;14(suppl 3):S211-S212
50. DelBello MP, Chang K, Welge JA, et al. A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder. Bipolar Disord. 2009;11(5):483-493
51. DelBello MP, Versavel M, Ice K, Keller D, Miceli J. Tolerability of oral ziprasidone in children and adolescents with bipolar mania, schizophrenia, or schizoaffective disorder. J Child Adolesc Psychopharmacol. 2008;18(5):491-499
52. Delbello MP, Schwiers ML, Rosenberg HL, Strakowski SM. A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry. 2002;41(10):1216-1223 (Pubitemid 38338041)
53. Findling RL, Nyilas M, Forbes RA, et al. Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2009;70(10):1441-1451
54. Haas M, Delbello MP, Pandina G, et al. Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study. Bipolar Disord. 2009;11(7):687-700
55. Haas M, Unis AS, Armenteros J, Copenhaver MD, Quiroz JA, Kushner SF. A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. J Child Adolesc Psychopharmacol. 2009;19(6):611-621
56. NCT00257166. Four week, double-blind, placebo controlled phase III trial evaluating the efficacy, safety and pharmacokinetics of flexible doses of oral ziprasidone in children and adolescents with bipolar I disorder (manic or mixed). PhRMA Web Synopsis 2008
57. Tohen M, Kryzhanovskaya L, Carlson G, et al. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry. 2007;164(10):1547-1556 (Pubitemid 350069734)
58. Tramontina S, Zeni CP, Ketzer CR, Pheula GF, Narvaez J, Rohde LA. Aripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit/hyperactivity disorder: a pilot randomized clinical trial. J Clin Psychiatry. 2009;70(5):756-764
59. Holtmann M, Bölte S, Poustka F. Rapid increase in rates of bipolar diagnosis in youth: "true" bipolarity or misdiagnosed severe disruptive behavior disorders? Arch Gen Psychiatry. 2008;65(4):477 (Pubitemid 351519897)
60. NCT00090311. Quetiapine Fumarate (Seroquel) Compared to Placebo in the Treatment of Children & Adolescents With Bipolar I Mania. Clinical Study Report Synopsis; 2008
61. Arango C, Robles O, Parellada M, et al. Olanzapine compared to quetiapine in adolescents with a first psychotic episode. Eur Child Adolesc Psychiatry. 2009; 18(7):418-428
62. Berger GE, Proffitt TM, McConchie M, et al. Dosing quetiapine in drug-naive firstepisode psychosis: a controlled, doubleblind, randomized, single-center study investigating efficacy, tolerability, and safety of 200 mg/day vs. 400 mg/day of quetiapine fumarate in 141 patients aged 15 to 25 years. J Clin Psychiatry. 2008;69(11):1702-1714
63. de Haan L, van Bruggen M, Lavalaye J, Booij J, Dingemans PM, Linszen D. Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. Am J Psychiatry. 2003;160(2):303-309 (Pubitemid 41110456)
64. Findling RL, Robb A, Nyilas M, et al. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry. 2008;165(11):1432-1441
65. Haas M, Eerdekens M, Kushner S, et al. Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: double-blind study. Br J Psychiatry. 2009;194(2):158-164
66. Jensen JB, Kumra S, Leitten W, et al. A comparative pilot study of secondgeneration antipsychotics in children and adolescents with schizophrenia-spectrum disorders. J Child Adolesc Psychopharmacol. 2008;18(4):317-326
67. Kryzhanovskaya L, Schulz SC, McDougle C, et al. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2009;48(1):60-70
68. Kumra S, Kranzler H, Gerbino-Rosen G, et al. Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biol Psychiatry. 2008;63(5): 524-529 (Pubitemid 351220784)
69. Kumra S, Frazier JA, Jacobsen LK, et al. Childhood-onset schizophrenia. A doubleblind clozapine-haloperidol comparison. Arch Gen Psychiatry. 1996;53(12):1090-1097 (Pubitemid 26422059)
70. Mozes T, Ebert T, Michal SE, Spivak B, Weizman A. An open-label randomized comparison of olanzapine versus risperidone in the treatment of childhood-onset schizophrenia. J Child Adolesc Psychopharmacol. 2006;16(4):393-403 (Pubitemid 44681460)
71. NCT00090324. A 6-week, international, multicenter, randomized, double-blind, parallel-group, placebo-controlled, phase IIIb study of the efficacy and safety of quetiapine fumarate (Seroquel) immediate- release tablets in daily doses of 400 mg and 800 mg compared with placebo in the treatment of adolescents with schizophrenia. Clinical Study Report Synopsis. 2008
72. NCT00257192. Six week, double-blind, placebo controlled phase III trial evaluating the efficacy, safety and pharmacokinetics of flexible doses of oral ziprasidone in adolescent subjects with schizophrenia. PhRMA Web Synopsis. 2010
73. Robb A. NCT00518323. A Randomized, Multicenter, Double-Blind, Weight-Based, Fixed-Dose, Parallel-Group, Placebo- Controlled Study of the Efficacy and Safety of Extended Release Paliperidone for the Treatment of Schizophrenia in Adolescent Subjects, 12 to 17 Years of Age. Johnson & Johnson Pharmaceutical Research & Development; 2009
74. Shaw P, Sporn A, Gogtay N, et al. Childhood-onset schizophrenia: a double-blind, randomized clozapine-olanzapine comparison. Arch Gen Psychiatry. 2006;63(7):721-730
75. Sikich L, Frazier JA, McClellan J, et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. [Erratum appears in Am J Psychiatry. 2008 Nov;165(11):1495] Am J Psychiatry. 2008;165(11):1420-1431
76. Sikich L, Hamer RM, Bashford RA, Sheitman BB, Lieberman JA. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology. 2004;29(1):133-145 (Pubitemid 38068023)
77. Spencer EK, Campbell M. Children with schizophrenia: diagnosis, phenomenology, and pharmacotherapy. Schizophr Bull. 1994;20(4):713-725 (Pubitemid 24373740)
78. Swadi HS, Craig BJ, Pirwani NZ, Black VC, Buchan JC, Bobier CM. A trial of quetiapine compared with risperidone in the treatment of first onset psychosis among 15- to 18-year-old adolescents. Int Clin Psychopharmacol. 2010;25(1):1-6
79. van Bruggen J, Tijssen J, Dingemans P, Gersons B, Linszen D. Symptom response and side-effects of olanzapine and risperidone in young adults with recent onset schizophrenia. Int Clin Psychopharmacol. 2003;18(6):341-346
80. Woods SW, Breier A, Zipursky RB, et al. Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. [Erratum appears in Biol Psychiatry. 2003 Aug 15;54(4):497] Biol Psychiatry. 2003;54 (4): 453-464
81. Yen YC, Lung F-W, Chong MY. Adverse effects of risperidone and haloperidol treatment in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28(2):285-290 (Pubitemid 38130134)
82. Kumra S, Jacobsen LK, Lenane M, et al. Childhood-onset schizophrenia: an openlabel study of olanzapine in adolescents. J Am Acad Child Adolesc Psychiatry. 1998; 37(4):377-385 (Pubitemid 28162891)
83. Ratzoni G, Gothelf D, Brand-Gothelf A, et al. Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. J Am Acad Child Adolesc Psychiatry. 2002;41(3):337-343 (Pubitemid 38338156)
84. Gilbert DL, Batterson JR, Sethuraman G, Sallee FR. Tic reduction with risperidone versus pimozide in a randomized, doubleblind, crossover trial. J Am Acad Child Adolesc Psychiatry. 2004;43(2):206-214
85. Sallee FR, Kurlan R, Goetz CG, et al. Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry. 2000;39(3):292-299 (Pubitemid 30127607)
86. Sallee FR, Nesbitt L, Jackson C, Sine L, Sethuraman G. Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder. Am J Psychiatry. 1997;154(8):1057-1062 (Pubitemid 27328819)
87. Sallee FR, Sethuraman G, Rock CM. Effects of pimozide on cognition in children with Tourette syndrome: interaction with comorbid attention deficit hyperactivity disorder. Acta Psychiatr Scand. 1994;90(1):4-9 (Pubitemid 24212165)
88. Scahill L, Leckman JF, Schultz RT, Katsovich L, Peterson BS. A placebo-controlled trial of risperidone in Tourette syndrome. Neurology. 2003;60(7):1130-1135 (Pubitemid 36418773)
89. Sehgal N. Short-term versus longer term pimozide therapy in Tourette's syndrome: a preliminary study. Neurology. 1999;52(4):874-877 (Pubitemid 29120205)
90. Bastiaens L. A non-randomized, open study with aripiprazole and ziprasidone for the treatment of aggressive behavior in youth in a community clinic. Community Ment Health J. 2009;45(1):73-77
91. Van Bellinghen M, De Troch C. Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: a double-blind, placebo-controlled pilot trial. J Child Adolesc Psychopharmacol. 2001;11(1):5-13 (Pubitemid 32295178)
92. Hellings JA, Zarcone JR, Reese RM, et al. A crossover study of risperidone in children, adolescents and adults with mental retardation. J Autism Dev Disord. 2006;36(3):401-411 (Pubitemid 43828664)
93. Khan SS, Mican LM. A naturalistic evaluation of intramuscular ziprasidone versus intramuscular olanzapine for the management of acute agitation and aggression in children and adolescents. J Child Adolesc Psychopharmacol. 2006;16(6):671-677 (Pubitemid 46175423)
94. Migliardi G, Spina E, D'Arrigo C, et al. Short- and long-term effects on prolactin of risperidone and olanzapine treatments in children and adolescents. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33 (8):1496-1501
95. Schulz E, Fleischhaker C, Remschmidt HE. Correlated changes in symptoms and neurotransmitter indices during maintenance treatment with clozapine or conventional neuroleptics in adolescents and young adults with schizophrenia. J Child Adolesc Psychopharmacol. 1996;6(2):119-131 (Pubitemid 26279068)
96. Bruggeman R, van der Linden C, Buitelaar JK, Gericke GS, Hawkridge SM, Temlett JA. Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study. J Clin Psychiatry. 2001;62(1):50-56 (Pubitemid 32154319)
97. Gothelf D, Falk B, Singer P, et al. Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. Am J Psychiatry. 2002;159(6):1055-1057 (Pubitemid 34586957)
98. Hrdlicka M, Zedkova I, Blatny M, Urbanek T. Weight gain associated with atypical and typical antipsychotics during treatment of adolescent schizophrenic psychoses: a retrospective study. Neuroendocrinol Lett. 2009;30(2):256-261
99. Wudarsky M, Nicolson R, Hamburger SD, et al. Elevated prolactin in pediatric patients on typical and atypical antipsychotics. J Child Adolesc Psychopharmacol. 1999;9 (4):239-245 (Pubitemid 30005078)
100. Alacqua M, Trifirò G, Arcoraci V, et al. Use and tolerability of newer antipsychotics and antidepressants: a chart review in a paediatric setting. Pharm World Sci. 2008;30(1):44-50 (Pubitemid 350172646)
101. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009;(16): 1765-1773
102. Crocq MA, Guillon MS, Bailey PE, Provost D. Orally disintegrating olanzapine induces less weight gain in adolescents than standard oral tablets. Eur Psychiatry. 2007;22(7):453-454 (Pubitemid 47600624)
103. Fleischhaker C, Heiser P, Hennighausen K, et al. Clinical drug monitoring in child and adolescent psychiatry: side effects of atypical neuroleptics. J Child Adolesc Psychopharmacol. 2006;16(3):308-316 (Pubitemid 43902427)
104. Fraguas D, Merchán-Naranjo J, Laita P, et al. Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics. J Clin Psychiatry. 2008;69(7):1166-1175 (Pubitemid 352031601)
105. Friedlander R, Lazar S, Klancnik J. Atypical antipsychotic use in treating adolescents and young adults with developmental disabilities. Can J Psychiatry. 2001;46(8):741-745
106. Jefferson AM, Markowitz JS, Brewerton TD. Atypical antipsychotics. J Am Acad Child Adolesc Psychiatry. 1998;37(12):1243-1244
107. Saito E, Correll CU, Gallelli K, et al. A prospective study of hyperprolactinemia in children and adolescents treated with atypical antipsychotic agents. J Child Adolesc Psychopharmacol. 2004;14(3):350-358 (Pubitemid 39473121)
108. McGlashan TH, Zipursky RB, Perkins D, et al. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry. 2006;163(5):790-799 (Pubitemid 44464525)
109. Correll CU, Penzner JB, Parikh UH, et al Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child Adol Psych Clin N Am. 2006;15(1):177-206 (Pubitemid 41735243)
110. Pringsheim T, Panagiotopoulos C, Davidson J, Ho J; CAMESA guideline group. Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth. J Can Acad Child Adolesc Psychiatry. 2011;20(3):218-233
111. Kompetenznetz Therapeutisches Drug Monitoring. Kinder- und Jugendpsychiatrie e.v. Available at: http://tdm-kjp.com/. Accessed September 19, 2011